YTHDF1 and ovarian carcinoma: A study of cisplatin-resistant ovarian cancer cell lines discovered that YTHDF1 was capable of resisting ovarian cancer cells by improving their CSC-like characteristics and promoting tumor progression by binding to m6A-modified three-part motif protein 29 (TRIM 29) and enhancing its translational efficiency [248].